Pharma News

SILVER SPRING, Md.

After Johnson & Johnson’s Zytiga put up impressive prostate cancer data at the American Society of Clinical Oncology meeting in June, Astellas and Pfizer needed a win for its rival medicine Xtan...

LISBON, Portugal—AstraZeneca’s Farxiga is already battling it out with its SGLT2 rivals in Type 2 diabetes.

(Reuters) - A European Medicines Agency (EMA) panel recommended the approval of Johnson & Johnson unit Janssen’s drug, guselkumab, for the treatment of plaque psoriasis in adults...

CAMBRIDGE, Mass.

Even after a contentious drug pricing ballot initiative in California fell short last year, the issue hasn’t gone away.

(Reuters) - Teva Pharmaceutical Industries Ltd (TEVA.

LONDON (Reuters) - AstraZeneca said it had agreed to sell the remaining rights to a portfolio of anesthetics to South Africa’s Aspen Group for up to $766 million, a year after Aspen bought t...

(Reuters) - A U.

LONDON, (Reuters) - Proposed United States budget cuts could put in jeopardy great progress in reducing global poverty and disease and lead to 5 million more deaths from AIDS alone, the philan...

(Reuters) - Amicus Therapeutics Inc said on Wednesday it would stop developing its experimental drug for healing wounds related to a rare skin disease, but shares of the company rose as invest...

Sage Therapeutics’ closely watched drug, brexanolone, did not do much better than a placebo in helping patients with a severe type of epilepsy, data from a phase 3 clinical trial show.